New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma

Published:2024-08-12 Issue:12 Volume:25 Page:1677-1689
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Hough Bruce¹²,Lytvynova Olga³,Sindel Ariel³⁴,Willard Patrick¹,Yazbeck Victor¹²

Affiliation:

1. Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA

2. Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

3. Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA

4. Department of Internal Medicine, Northeast Ohio Medical University, Akron, OH, USA

Funder

National Cancer Institute

National Institutes of Health

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2393759

Reference67 articles.

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

2. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

3. Lymphoma Research Foundation. Diffuse large B-Cell lymphoma - lymphoma research foundation. 2023 Jun 26. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/?gad_source=1&gclid=Cj0KCQjw2ou2BhCCARIsANAwM2E82zNccaxxjEGRGm_blAFj-CdunEYA0jizIkMbNpF9YriE8DiLOX0aAs3rEALw_wcB

4. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

5. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab